ZA201402492B - Polymorphic form of pridopidine hydrochloride - Google Patents
Polymorphic form of pridopidine hydrochlorideInfo
- Publication number
- ZA201402492B ZA201402492B ZA2014/02492A ZA201402492A ZA201402492B ZA 201402492 B ZA201402492 B ZA 201402492B ZA 2014/02492 A ZA2014/02492 A ZA 2014/02492A ZA 201402492 A ZA201402492 A ZA 201402492A ZA 201402492 B ZA201402492 B ZA 201402492B
- Authority
- ZA
- South Africa
- Prior art keywords
- polymorphic form
- pridopidine hydrochloride
- pridopidine
- hydrochloride
- polymorphic
- Prior art date
Links
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170496 | 2011-09-07 | ||
| US201161533550P | 2011-09-12 | 2011-09-12 | |
| PCT/EP2012/067371 WO2013034622A1 (en) | 2011-09-07 | 2012-09-06 | Polymorphic form of pridopidine hydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201402492B true ZA201402492B (en) | 2015-07-29 |
Family
ID=47831564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/02492A ZA201402492B (en) | 2011-09-07 | 2014-04-04 | Polymorphic form of pridopidine hydrochloride |
Country Status (14)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| DK2146961T3 (da) | 2007-04-12 | 2014-04-28 | Ivax Int Gmbh | N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler |
| US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| HUE054783T2 (hu) * | 2013-06-21 | 2021-09-28 | Prilenia Neurotherapeutics Ltd | Pridopidin Huntington-kór kezelésében |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) * | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AU2016222796B2 (en) | 2015-02-25 | 2021-07-15 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) * | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| CA3015512C (en) | 2016-02-24 | 2024-01-16 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| BR112019003731A2 (pt) | 2016-08-24 | 2019-07-16 | Prilenia Therapeutics Dev Ltd | aplicação de pridopidina para tratamento de distonias |
| PL3504187T3 (pl) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd. | Stosowanie pridopidyny w leczeniu zaburzeń czynnościowych |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| EP3570940B1 (en) | 2017-01-20 | 2023-12-13 | Prilenia Neurotherapeutics Ltd. | Pridopidine for use in the treatment of fragile x syndrome |
| EP3357909A1 (en) | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
| MX2020001836A (es) | 2017-08-14 | 2020-08-10 | Prilenia Neurotherapeutics Ltd | Metodo para tratar esclerosis lateral amiotrofica con pridopidina. |
| BR112020004045A2 (pt) | 2017-08-30 | 2020-09-01 | Prilenia Neurotherapeutics Ltd. | formas de dosagem de elevada concentração de pridopidina |
| CN111343982A (zh) * | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| GB0329236D0 (en) * | 2003-12-17 | 2004-01-21 | Arakis Ltd | Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride |
| ES2346452T3 (es) | 2004-06-08 | 2010-10-15 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina. |
| HUE029790T2 (hu) * | 2004-10-13 | 2017-04-28 | Teva Pharmaceuticals Int Gmbh | Eljárás 4-(3-metánszulfonil-fenil)-l-N-propil-piperidin elõállítására |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| DK2146961T3 (da) | 2007-04-12 | 2014-04-28 | Ivax Int Gmbh | N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler |
| WO2008155357A2 (en) | 2007-06-18 | 2008-12-24 | A. Carlsson Research Ab | Use of dopamine stabilizers |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| EP2900330A4 (en) | 2012-09-27 | 2016-05-25 | Teva Pharma | LAQUINIMOD AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| HK1211483A1 (en) | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
-
2012
- 2012-09-06 EP EP12755869.0A patent/EP2753603B1/en active Active
- 2012-09-06 MX MX2014002731A patent/MX343620B/es active IP Right Grant
- 2012-09-06 JP JP2014528965A patent/JP6189299B2/ja not_active Expired - Fee Related
- 2012-09-06 CA CA 2847736 patent/CA2847736A1/en not_active Abandoned
- 2012-09-06 WO PCT/EP2012/067371 patent/WO2013034622A1/en active Application Filing
- 2012-09-06 BR BR112014005389A patent/BR112014005389A8/pt not_active IP Right Cessation
- 2012-09-06 US US14/342,253 patent/US9006445B2/en active Active
- 2012-09-06 CN CN201280043794.9A patent/CN103958469B/zh active Active
- 2012-09-06 EA EA201490569A patent/EA023462B1/ru not_active IP Right Cessation
- 2012-09-06 AU AU2012306386A patent/AU2012306386B2/en not_active Ceased
- 2012-09-06 KR KR20147009105A patent/KR20140075703A/ko not_active Ceased
- 2012-09-06 ES ES12755869.0T patent/ES2639052T3/es active Active
-
2014
- 2014-02-25 IL IL231149A patent/IL231149A0/en unknown
- 2014-04-04 ZA ZA2014/02492A patent/ZA201402492B/en unknown
-
2017
- 2017-05-31 JP JP2017107986A patent/JP2017206516A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2847736A1 (en) | 2013-03-14 |
| CN103958469A (zh) | 2014-07-30 |
| KR20140075703A (ko) | 2014-06-19 |
| JP6189299B2 (ja) | 2017-08-30 |
| EP2753603A1 (en) | 2014-07-16 |
| EA201490569A1 (ru) | 2014-09-30 |
| BR112014005389A2 (pt) | 2017-03-28 |
| AU2012306386A1 (en) | 2014-04-17 |
| MX2014002731A (es) | 2014-04-30 |
| US20140315951A1 (en) | 2014-10-23 |
| EA023462B1 (ru) | 2016-06-30 |
| JP2014525470A (ja) | 2014-09-29 |
| WO2013034622A1 (en) | 2013-03-14 |
| HK1199728A1 (en) | 2015-07-17 |
| JP2017206516A (ja) | 2017-11-24 |
| EP2753603B1 (en) | 2017-06-21 |
| US9006445B2 (en) | 2015-04-14 |
| IL231149A0 (en) | 2014-04-30 |
| ES2639052T3 (es) | 2017-10-25 |
| BR112014005389A8 (pt) | 2018-04-03 |
| CN103958469B (zh) | 2016-04-20 |
| AU2012306386B2 (en) | 2017-06-15 |
| MX343620B (es) | 2016-11-11 |
| NZ623344A (en) | 2015-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201402492B (en) | Polymorphic form of pridopidine hydrochloride | |
| IL232599A (en) | Hydrobromide salt of peridofidine | |
| EP2596675A4 (en) | METHODS OF MANAGING MULTIPLE TIME ADVANCE GROUPS | |
| HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
| LT2709986T (lt) | Ivakaftoro deuterinti dariniai | |
| SI2707368T1 (sl) | Polimorf linagliptin benzoata | |
| EP2648519A4 (en) | NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE | |
| EP2776393A4 (en) | NAMPT INHIBITORS | |
| SI2751081T1 (sl) | Polimorfna oblika kalcijevega pitavastatinata | |
| PL2552910T3 (pl) | Nowy polimorf | |
| GB201121175D0 (en) | Method of electroplating | |
| EP2680843A4 (en) | DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS | |
| GB2512737B (en) | Micro-Fermentation of cocoa | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| IL230977A (en) | A crystalline form of relapaldib | |
| ZA201400407B (en) | N-hetero-ring-substituted amide derivative | |
| PL2714707T3 (pl) | Krystalizacja chlorowodorku epirubicyny | |
| GB201113815D0 (en) | Multi-photon isomerisation of transcombretastatins | |
| PL395425A1 (pl) | Sposób wytwarzania chlorowodorku 2-amino-N-tert-butylo-2- cyjanoacetamidu | |
| GB201102475D0 (en) | Method of reducing offset | |
| EP2928469A4 (en) | POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS | |
| GB201108346D0 (en) | Polymorphic form of compound | |
| GB201103838D0 (en) | Polymorphic form | |
| GB201103839D0 (en) | Polymorphic form | |
| GB201103840D0 (en) | Polymorphic form |